TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27181565

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 672

Group type: COMPARATOR
Intervention: PCI with DES
Number of subjects: 672
Study: 25066366

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collaborative care (three-session psycho-educational intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy and Collaborative care
Number of subjects: 0
Study: 23235363

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg and aliskiren 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg and eplerenone 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: telmisartan 160 mg as monotherapy
Number of subjects: 18
Study: 19843596

Group type: COMPARATOR
Intervention: VCPAP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BCPAP
Number of subjects: 30
Study: 18591363

Group type: EXPERIMENTAL
Intervention: 12-month fruit and vegetable intervention
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Maintainers of 5 or more servings per day
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Failed to progress
Number of subjects: 1277
Study: 16078963

Group type: EXPERIMENTAL
Intervention: Newer drugs
Number of subjects: 6256

Group type: COMPARATOR
Intervention: Older agents
Number of subjects: 6256
Study: 12269790

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10025924

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) 13.5 x 10(6) units per week in divided doses
Number of subjects: 35
Study: 7741245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antioxidants plus Vitamin D
Number of subjects: 48
Study: 1434726

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 321

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 321

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 321
Study: 3902105

Group type: EXPERIMENTAL
Intervention: Pimozide 2 mg or 6 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Thioridazine 25 mg or 75 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined administration of pimozide and thioridazine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Retrospective placebo group
Number of subjects: 106
Study: 30810462

Group type: EXPERIMENTAL
Intervention: Hydrogel bulking agent (Bulkamid®)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Collagen gel (Contigen®)
Number of subjects: 291
Study: 30268057

Group type: EXPERIMENTAL
Intervention: Home visitation (Healthy Families New York)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no home visitation)
Number of subjects: 104
Study: 26306566

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing β-hydroxy-β-methylbutyrate (HMB), glutamine and arginine (3g HMB, 14g glutamine, 14g arginine daily for 6 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 31
Study: 24622685

Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both SSG and HIIT
Number of subjects: 19
Study: 23429675

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (n = 176)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Brief intervention (n = 175)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Subgroup receiving multidisciplinary intervention (n = 60)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Validation study (n = 28)
Number of subjects: 351
Study: 21352670

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional standard chest physical therapy
Number of subjects: 22
Study: 19586546

Group type: EXPERIMENTAL
Intervention: Osteosynthesis with angle-stable plate
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Primary hemiarthroplasty
Number of subjects: 162

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 162
Study: 17725180

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg capsules (Ranbaxy Laboratories Ltd.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zerit 40 mg capsules (Bristol-Myers Squibb)
Number of subjects: 40
Study: 15195000

Group type: EXPERIMENTAL
Intervention: [123I]-MIBG wash out rate (WOR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Group A (higher WOR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inferior and septal wall [123I]-MIBG uptake on 4 hour SPET
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIBI SPET rest regional uptake
Number of subjects: 11
Study: 11329735

Group type: EXPERIMENTAL
Intervention: Suggestions to improve informed consent processes in clinical trials
Number of subjects: 0
Study: 9891830

Group type: EXPERIMENTAL
Intervention: Angioplasty with high Lp (a) levels (above 0.30 g/l)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Coronary artery disease without restenosis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: No angiographic or clinical restenosis
Number of subjects: 59
Study: 7573093

Group type: EXPERIMENTAL
Intervention: Regular nicotinic acid
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sustained-release nicotinic acid
Number of subjects: 110
Study: 2248105

Group type: EXPERIMENTAL
Intervention: Ecolyzer Model 210
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ecolyzer Series 2000
Number of subjects: 29
Study: 7241682

Group type: EXPERIMENTAL
Intervention: Cinoxacin 500 mg twice daily for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 160-800 mg twice daily for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 30427227

Group type: EXPERIMENTAL
Intervention: Drop height of 20 cm
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Drop height of 35 cm
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Drop height of 50 cm
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Drop heights (20, 35, 50 cm)
Number of subjects: 239
Study: 28646784

Group type: EXPERIMENTAL
Intervention: 30min of morning light therapy (5,000lx; blue-enriched polychromatic light, 17,000K)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham session (200lx, polychromatic light, 5,000K)
Number of subjects: 48
Study: 26216608

Group type: EXPERIMENTAL
Intervention: Nasal balloon autoinflation 3 times daily for 1-3 months plus usual care
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study: 22935321

Group type: EXPERIMENTAL
Intervention: High blueberry dose (75 g)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low blueberry dose (35 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (ascorbic acid and sugar matching high blueberry dose)
Number of subjects: 14
Study: 22044987

Group type: EXPERIMENTAL
Intervention: Upper-extremity rehabilitation robotic training
Number of subjects: 27
Study: 20038285

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASA with dipyridamole
Number of subjects: 0
Study: 17197849

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 36

Group type: COMPARATOR
Intervention: Poligeline
Number of subjects: 36
Study: 14747230

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 50
Study: 11133899

Group type: EXPERIMENTAL
Intervention: Acute normoxic exercise
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acute hypoxic exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intermittent training in normoxia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intermittent training in hypoxia
Number of subjects: 32
Study: 9754896

Group type: EXPERIMENTAL
Intervention: Foot pump mechanical compression
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 40
Study: 8141279

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 mg.kg ideal body wt‐1.day‐1)
Number of subjects: 9
Study: 2183716

Group type: EXPERIMENTAL
Intervention: Endotracheal tobramycin (40 mg every 8 h)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (endotracheally every 8 h)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Endotracheal tobramycin
Number of subjects: 85
Study: 6107407

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 3000 units (75 micrograms) daily
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol 1 microgram daily
Number of subjects: 7
Study: 31237435

Group type: EXPERIMENTAL
Intervention: Emergency coronary angiography (CAG) performed within 2 hours
Number of subjects: 166

Group type: COMPARATOR
Intervention: Deferred coronary angiography (CAG) performed before discharge
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both groups receive routine care in the intensive cardiac care unit, including therapeutic hypothermia
Number of subjects: 166
Study: 31255307

Group type: EXPERIMENTAL
Intervention: Low-frequency WBV (30 Hz)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-frequency WBV (50 Hz)
Number of subjects: 24
Study: 28152124

Group type: EXPERIMENTAL
Intervention: Subretinal injection of 0.1 mL of a gene therapy solution containing 1 × 10^11 viral particles
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 5
Study: 24796864

Group type: EXPERIMENTAL
Intervention: diet
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: diet + exercise
Number of subjects: 439

Group type: COMPARATOR
Intervention: no-lifestyle-change control
Number of subjects: 439
Study: 23172847

Group type: EXPERIMENTAL
Intervention: Lifestyle treatment programme with physiotherapist involvement
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lifestyle treatment programme without physiotherapist involvement
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-intervention comparison group of children with obesity
Number of subjects: 64
Study: 21216670

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg once per day, orally) for 3 months starting 5-10 days after stroke onset
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo for 3 months starting 5-10 days after stroke onset
Number of subjects: 118
Study: 19381809

Group type: EXPERIMENTAL
Intervention: Psycho‐educational program (eight sessions)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 169
Study: 17382151

Group type: EXPERIMENTAL
Intervention: Lidocaine ointment combined with tramadol drops 1 mg/kg per os 40 minutes before the procedure (group 2)
Number of subjects: 77

Group type: COMPARATOR
Intervention: 5% lidocaine ointment 5 mL per rectum 10 minutes before the procedure (group 1)
Number of subjects: 77
Study: 15245526

Group type: EXPERIMENTAL
Intervention: Wet wrap therapy (WWT) with 1% hydrocortisone (HC) applied once in the morning for 2 weeks, wet wraps twice daily for week 1, and only at night for week 2
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) applied twice daily without wet wraps
Number of subjects: 19
Study: 11753990

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT), mean total dose 65 grays (Gy; 62.3-70 Gy)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Deferred treatment (DT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (age-matched, n=68)
Number of subjects: 108
Study: 9669469

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP) pulse therapy (2 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7838445

Group type: EXPERIMENTAL
Intervention: Min-Max method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Average method
Number of subjects: 0
Study: 3154322

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic versus single digoxin dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for future studies
Number of subjects: 0
Study: 29471557

Group type: EXPERIMENTAL
Intervention: Completely metal-free ceramic system (matrix of aluminum and zirconium oxide)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anatomically identical metallic knee system (cobalt-chromium alloy)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (metal-free ceramic and metallic knee system)
Number of subjects: 80
Study: 28376725

Group type: EXPERIMENTAL
Intervention: Nutrition training for midlevel providers (MLPs)
Number of subjects: 776
Study: 26092311

Group type: EXPERIMENTAL
Intervention: Dopamine D2-receptor antagonist sulpiride (400 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22752050

Group type: EXPERIMENTAL
Intervention: Risedronate 150-mg once a month
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Risedronate 5-mg daily
Number of subjects: 1292
Study: 20964572

Group type: EXPERIMENTAL
Intervention: 2% sunflower oleodistillate (SO) cream applied twice a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydrocortisone butyro-propionate 1 mg/g applied twice a day
Number of subjects: 80
Study: 18164562

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 1mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: raloxifene HCl 60 mg
Number of subjects: 88
Study: 16418760

Group type: EXPERIMENTAL
Intervention: Gx (500 mg capsules containing 6 mg synephrine, 150 mg caffeine, and 150 mg catechin polyphenols)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gx
Number of subjects: 20
Study: 14593356

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg BID loading dose for 2 days and 250 mg BID for subsequent 5 days)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose and 75 mg/day for subsequent 6 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no ticlopidine)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no clopidogrel)
Number of subjects: 37
Study: 11001866

Group type: EXPERIMENTAL
Intervention: 30 mg/day prednisolone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8620255

Group type: EXPERIMENTAL
Intervention: Intervention program (self-instructional module, audiotape, health consultation with physician/nurse, follow-up consultation with peer health model)
Number of subjects: 104
Study: 1727109

Group type: EXPERIMENTAL
Intervention: 2400 cGy cranial irradiation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1800 cGy cranial irradiation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no irradiation)
Number of subjects: 35
Study: 6389477

Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg twice daily for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29982430

Group type: EXPERIMENTAL
Intervention: Conscious sedation with midazolam and fentanyl
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 103
Study: 28734105

Group type: EXPERIMENTAL
Intervention: Median Nerve Neural Mobilization (MNNM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting List Control Group (WLCG)
Number of subjects: 60
Study: 26672923

Group type: EXPERIMENTAL
Intervention: Open lung approach
Number of subjects: 200

Group type: COMPARATOR
Intervention: Acute Respiratory Distress Syndrome network protocol
Number of subjects: 200
Study: 25363108

Group type: EXPERIMENTAL
Intervention: Educational intervention based on precede-proceed model
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 128
Study: 22609079

Group type: EXPERIMENTAL
Intervention: Ligation of intersphincteric fistula tract (LIFT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anorectal advancement flap (ARAF)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: LIFT
Number of subjects: 39

Group type: COMPARATOR
Intervention: ARAF
Number of subjects: 39
Study: 20956826

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 93
Study: 17431063

Group type: EXPERIMENTAL
Intervention: 5 mg of diazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15938034

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 12131781

Group type: EXPERIMENTAL
Intervention: Loxiglumide 300 mg/d
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Loxiglumide 600 mg/d
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Loxiglumide 1200 mg/d
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 10220845

Group type: EXPERIMENTAL
Intervention: Supervised physical therapy rehabilitation (1 h, twice weekly) with emphasis on balance training
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard information regarding early ankle mobilization (Control group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Supervised physical therapy rehabilitation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 7823670

Group type: EXPERIMENTAL
Intervention: Face-washing intervention program plus mass topical antibiotic treatment
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Mass topical antibiotic treatment only (Control)
Number of subjects: 1417

Group type: EXPERIMENTAL
Intervention: Clean face at two or more follow-up visits
Number of subjects: 1417
Study: 2352788

Group type: EXPERIMENTAL
Intervention: Lithium carbonate for 10 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 484262

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 19
Study: 31309627

Group type: EXPERIMENTAL
Intervention: Topical product containing 3 antioxidants (pre‐tocopheryl®, retinaldehyde, glycylglycine ole‐amide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Positive antioxidant control cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study: 28412590

Group type: EXPERIMENTAL
Intervention: Ramucirumab + FOLFIRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramucirumab treatment for CEA ≤10 subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramucirumab treatment for CEA >10 subgroup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramucirumab vs. placebo for CEA ≤10 subgroup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramucirumab vs. placebo for CEA >10 subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramucirumab treatment
Number of subjects: 0
Study: 25468160

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (25 mg daily for 72 weeks)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Number of subjects: 283
Study: 23245591

Group type: COMPARATOR
Intervention: Meperidine (0.7 mg/kg) with sham patient controlled analgesia (Group M)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 μg/kg with patient-controlled analgesia pump (Group R1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.8 μg/kg with patient-controlled analgesia pump (Group R2)
Number of subjects: 90
Study: 21460373

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) combined with Antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) in children on ART
Number of subjects: 0
Study: 19501937

Group type: EXPERIMENTAL
Intervention: diabetes-specific feed
Number of subjects: 25

Group type: COMPARATOR
Intervention: standard feed
Number of subjects: 25
Study: 17522096

Group type: EXPERIMENTAL
Intervention: Combined treatment (exercise and manipulation)
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (age, work status, age of leaving school, pain and disability, quality of life, beliefs)
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Episode length at study entry
Number of subjects: 1334
Study: 14979810

Group type: EXPERIMENTAL
Intervention: Deterministic sequence training with inclusion instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deterministic sequence training with exclusion instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic sequence training with inclusion instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probabilistic sequence training with exclusion instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial‐by‐trial generation test under inclusion conditions after longer training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial‐by‐trial generation test under exclusion conditions after longer training
Number of subjects: 0
Study: 11820689

Group type: EXPERIMENTAL
Intervention: Crank rate of 70 rev x min(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crank rate of 80 rev x min(‐1)
Number of subjects: 20
Study: 9543282

Group type: EXPERIMENTAL
Intervention: i.v. corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: untreated asthmatics
Number of subjects: 0